Pharmacies and Drug Retailers (U.S.) — NAICS 456110

NAICS = North American Industry Classification System, the federal standard for grouping businesses by activity.

1. Overview

Pharmacies and drug retailers are the stores and mail-order operations that dispense prescription and over-the-counter (OTC) medicines to the public — from the corner CVS or Walgreens, to a single-location independent drugstore, to a mail pharmacy that ships a 90-day supply to your door. It is a large, everyday-essential business: Americans filled roughly 7.1 billion retail and long-term-care prescriptions in 2024 [6], and the dedicated pharmacy and drugstore establishments the federal government counts under this code booked about $544 billion in sales in 2022 [3].

It is a defensive-demand business but not automatically a defensive-profit one. People take their medicines in good times and bad, and the customer base is aging and increasingly chronically ill — yet the storefront-pharmacy business itself has been one of the most financially stressed corners of U.S. retail. Reimbursement per prescription has been squeezed for a decade by the middlemen who actually set pharmacy pay (pharmacy benefit managers), front-of-store sales have leaked to Amazon and mass merchants, and the result has been mass closures: more than 2,200 pharmacies shut in 2024 alone [16], Rite Aid liquidated entirely [13], and Walgreens was taken private after its public-market value collapsed [12].

There are two very different ways to think about participating here. Public-market routes are mostly indirect and increasingly consolidated: one large listed pure-play chain (CVS Health) remains, while the rest of the value has migrated to diversified giants where pharmacy is one segment among insurance and drug-benefit businesses (Cigna, UnitedHealth), to mass and grocery retailers (Walmart, Kroger, Costco), or to online entrants (Amazon). Private routes are the roughly 19,000 independent community pharmacies, private-equity-owned Walgreens, private grocers such as Publix and H-E-B, pharmacy real estate, private credit, and startups such as Mark Cuban's Cost Plus Drugs. The common thread: the economics reward scale and, above all, control of the drug-benefit "middleman" layer — which is why the winners increasingly own a pharmacy benefit manager rather than just a store.

2. What it is and how it is structured

Scope (what is in 456110). The code covers establishments "generally known as pharmacies and drug retailers engaged in retailing prescription or nonprescription drugs and medicines" [1]. That includes chain drugstores; independent community pharmacies; pharmacies whose primary activity is retail dispensing (specialty, compounding, central-fill, institutional, and home-delivery); stand-alone mail-order pharmacies; and online pharmacies — plus the front-of-store merchandise these outlets also sell (cosmetics, snacks, greeting cards, health aids) [1].

What it explicitly excludes — important, because it drives a real undercount (Section 3):

• Pharmacy benefit managers (PBMs) — the firms that administer drug benefits for insurers and employers — are classified in NAICS 524292 (Pharmacy Benefit Management and Other Third-Party Administration), not here [1]. This matters enormously because PBMs, not the stores, control most of the industry's profit pool.
• Vitamin and supplement retailers fall under NAICS 456191 (Food (Health) Supplement Retailers) [1].
• Adjacent health-and-personal-care retail: 456120 (cosmetics/beauty), 456130 (optical goods), 456199 (other health and personal care) [1].
• Drug wholesalers/distributors (McKesson, Cencora, Cardinal Health) sit in 424210 (Drugs and Druggists' Sundries Merchant Wholesalers), not retail [1].
• Critically, a pharmacy counter inside a supermarket, supercenter, or warehouse club is not counted here. Because the Census classifies an establishment by its primary activity, Walmart, Costco, Sam's Club, and Kroger pharmacy sales are folded into warehouse-club/supercenter (455211) and grocery (445110) codes — even though those operators dispense a large and growing share of the nation's prescriptions.

What a pharmacy actually is. It combines retail assets — location, inventory, technology, customer traffic — with licensed healthcare labor and a web of contracts with insurers, government programs, and PBMs. That contractual layer, not the storefront, is what makes it a payer-controlled service network rather than a simple store.

Ownership mix. Three layers coexist: (1) large national chains, now effectively CVS plus the newly private Walgreens after Rite Aid's exit; (2) mass and grocery retailers that run pharmacies as a traffic-driving department; and (3) roughly 19,000 independent, often family-owned community pharmacies [14]. The federal data show about 41,792 establishments but only 19,676 firms [2][3] — consistent with a market of a few very large chains operating thousands of stores each, alongside thousands of single-location owners. The federal statistics do not provide a public-versus-private ownership split.

3. How big it is (federal figures)

The government's ground-truth statistics for NAICS 456110:

Two caveats on reading the table: the receipts and concentration figures are from the 2022 Economic Census while employment and payroll are from 2023 County Business Patterns (CBP) — different years, not a single-period income statement — and the Small Business Administration (SBA) threshold is a federal small-business classification rule, not an estimate of market size [2][3][4].

Concentration. The four largest firms took 71% of the code's revenue, the top 8 took 76.3%, the top 20 took 79.2%, and the top 50 took 82% [3]; the Herfindahl-Hirschman Index (HHI, a standard concentration gauge where 10,000 = pure monopoly) was 1,710.8, which regulators treat as moderately-to-highly concentrated [3]. In plain terms: a handful of chains dominate, then a very long tail of small independents.

Two undercount caveats. First, a coverage gap in the federal figures themselves: CBP and the Economic Census count employer establishments with paid employees, so they miss the smallest nonemployer, owner-operated pharmacies and institutional pharmacies classified outside the retail-employer universe [2][5]. This is not a government-dominated industry, so that omission is modest. Second, and larger, a channel-classification gap: the $544 billion figure meaningfully understates total U.S. pharmacy dispensing because the pharmacy sales embedded in Walmart, Costco, Kroger, Sam's Club, and other non-drugstore formats are booked under other NAICS codes (Section 2). Industry trackers that count prescriptions across all channels put total U.S. prescription-dispensing revenue at roughly $683 billion in 2024, up about 9% year over year [7]; net national spending on medicines rose 11.4% to $487 billion in 2024 [6]. So the "pharmacy economy" that matters is larger and faster-growing than the drugstore-only slice this code captures — but the incremental growth is disproportionately in mail, specialty, and grocery/mass channels, not the traditional corner drugstore.

The federal file provides no industry profit, EBITDA (earnings before interest, taxes, depreciation, and amortization), same-store sales, prescription volume, gross margin, or capital spending. Those are absent here; no estimates are substituted for them.

4. The investable universe

There is only one large listed pure-play chain left; most public exposure is indirect. Tickers and scale figures below are for the "how to invest" discussion (Section 10) — the industry does not trade as a single unit.

Publicly traded (relevant exposure):

Drug distributors McKesson (NYSE: MCK), Cencora (NYSE: COR), and Cardinal Health (NYSE: CAH) are adjacent public plays — they supply the pharmacies and run buying/banner groups for independents — but sit in wholesale (424210), not this code.

Private and other owners:

• Walgreens Boots Alliance — the #2 chain (8,560 U.S. locations at fiscal year-end August 2024 [11]) — was taken private by Sycamore Partners in a deal worth up to $23.7 billion that closed August 28, 2025 [12]; no longer publicly traded.
• Rite Aid — formerly the #3 chain — filed its second Chapter 11 in two years in May 2025 and fully liquidated, closing its last stores in October 2025 [13]. No longer exists.
• ~18,984 independent community pharmacies (June 2024) [14] — privately owned, often affiliated with distributor-run banner networks such as Health Mart (McKesson) or Good Neighbor Pharmacy (Cencora).
• Private grocers with large pharmacy footprints: Publix (employee-owned, with an active pharmacy-acquisition program), H-E-B (partner-owned), Meijer (family-owned), and Wegmans [32]; Giant Eagle (family-owned, pending sale to Kroger [30]).
• Mark Cuban Cost Plus Drugs — private online "cost-plus" pharmacy (acquisition cost + 15% + a small fill fee) [28].

Bottom line: a general investor cannot buy "the drugstore industry" cleanly. The listed vehicles are either one stressed pure-play (CVS), diversified insurance/PBM conglomerates (CI, UNH), or retailers where pharmacy is a minority department (WMT, KR, COST, ACI, AMZN).

5. How the money works

A pharmacy has two profit engines: the back of store (the prescription counter) and the front of store (general merchandise). For a traditional drugstore, prescriptions are the large majority of revenue. The basic economic equation is:

Pharmacy reimbursement and fees − drug acquisition cost − pharmacist and technician labor − occupancy − technology − compliance and other operating costs.

The core unit economics — reimbursement per prescription. A pharmacy buys a drug at an acquisition cost, then gets reimbursed by a PBM or payer at a contracted rate (typically a benchmark such as the National Average Drug Acquisition Cost, or a discount off Average Wholesale Price) plus a dispensing fee. Gross profit per script = (reimbursement − acquisition cost) + dispensing fee. The whole industry's stress lives on this line: the pharmacy usually does not control the final price, and PBMs have driven reimbursement rates and dispensing fees down for years. PBMs also set network access, preferred-pharmacy status, formularies, audits, and post-sale adjustments. Spread pricing — where a PBM bills a plan sponsor more than it reimburses the pharmacy and keeps the difference — and opaque reimbursement formulas have drawn Federal Trade Commission (FTC) scrutiny, especially for independents [20][21]. Independent pharmacies' gross margin fell to 19.7% in 2023, the lowest in a decade of NCPA (National Community Pharmacists Association) tracking [14].

Brand vs. generic vs. specialty. Economics differ sharply by drug type. Generics are cheap to buy and reimbursed above cost, so they carry high percentage margins and are the profit backbone (roughly nine of ten U.S. prescriptions are generic). Brand-name drugs move huge dollars at thin percentage margins. Specialty drugs (complex, high-cost biologics) are enormous in dollar terms and increasingly the majority of dispensing revenue at the big integrated players [7], but they run on thin percentage spreads and require prior authorization, cold-chain handling, and more working capital.

Other revenue streams: OTC medicines and general merchandise, cash-pay and discount-card scripts, compounding and infusion, and — increasingly — vaccinations and pharmacist-led clinical services (e.g., CVS MinuteClinic) that add higher-margin traffic.

The metrics owners actually watch: prescription volume and script market share (often on a 30-day-equivalent basis); generic dispensing rate; gross profit per script after fees; payer and generic/specialty mix; front-of-store same-store sales (shrinking as shoppers move online); inventory turns; pharmacy labor productivity; and lease/debt load.

DIR fees and the 2024 reset. In Medicare's drug program, PBMs for years clawed back "direct and indirect remuneration" (DIR) after a prescription was filled, creating unpredictable retroactive fees that hammered pharmacy cash flow. A Centers for Medicare & Medicaid Services (CMS) rule moved these to the point of sale beginning in 2024, improving fee transparency (though not necessarily total pay) [19].

The shift to cost-plus/transparent pricing. In response to reimbursement complexity, major dispensers have adopted acquisition-cost-plus-fee models — CVS's CostVantage, Walgreens' equivalent, Amazon Pharmacy, and Cost Plus Drugs. CVS said it completed the transition to cost-based reimbursement across its commercial, third-party, Medicare, and Medicaid business by the end of 2025 [10].

Where the real money is: vertical integration. The single most important economic fact in this industry is that the profit has migrated out of the store. Five of the largest "pharmacies" run their dispensing inside vertically integrated groups that also own a PBM and, in several cases, an insurer: CVS Caremark, Express Scripts (Cigna), OptumRx (UnitedHealth), CarelonRx (Elevance), and CenterWell (Humana) [7]. The PBM sets the reimbursement, negotiates manufacturer rebates, steers patients to affiliated mail/specialty pharmacies, and captures spread — so the same corporate parent that squeezes the retail counter often profits on the benefit-management side. That is why CVS's health-benefits and Caremark segments, not its stores, drive its valuation, and why standalone chains without a PBM (Rite Aid, and arguably public-market Walgreens) struggled to survive.

6. What drives demand

• Demographics and chronic disease. An aging population and rising rates of diabetes, cardiovascular disease, and other chronic conditions steadily lift prescription volume. Retail drugs represent about 83% of all U.S. medicine use [6].
• The GLP-1 boom. Obesity and diabetes drugs (GLP-1s — glucagon-like peptide-1 receptor agonists such as semaglutide) alone accounted for 29% of U.S. medicine-spending growth in 2024 [6] — a volume tailwind but a mixed blessing for margin (high dollar value, thin percentage spread).
• Insurance coverage and affordability. Medicare Part D and Medicaid enrollment, commercial coverage, and benefit design determine who can afford to fill scripts. Medicare Part D's redesign under the Inflation Reduction Act (IRA) set a $2,000 annual out-of-pocket cap on covered drugs (2025; indexed to roughly $2,100 in 2026), capped covered insulin cost-sharing at $35, and eliminated cost-sharing for certain recommended adult vaccines — changes that can lift adherence and fill rates while shifting more cost to plans, manufacturers, and the federal government [19].
• New drug launches and price inflation. A wave of new products drove spending growth [6]; list-price inflation also raises dollar revenue per script.
• Specialty and complex medicines. Specialty drugs and biologics raise revenue per prescription and require more clinical support — attractive growth, but greater reimbursement and compliance risk.
• Vaccinations and clinical services. Flu, COVID, RSV, and shingles immunizations became a meaningful traffic and revenue driver, though volumes have normalized off pandemic peaks [9].
• Convenience and channel shift. Home delivery, 90-day mail fills, auto-refill, and medication packaging (e.g., Amazon Pharmacy/PillPack) increasingly shape where demand lands — favoring mail, mass, and online over the traditional drugstore [31].

7. Regulation

Pharmacy is one of the most heavily regulated retail categories in America:

• State boards of pharmacy license pharmacists and pharmacies and set staffing, scope-of-practice, ownership, and dispensing rules — which vary by state.
• U.S. Food and Drug Administration (FDA) regulates drug products, OTC labeling, recalls, and compounding.
• Drug Supply Chain Security Act (DSCSA) requires pharmacies to participate in electronic systems that trace prescription medicines and screen out counterfeit or illegitimate products; FDA exemptions for small dispensers extend certain deadlines through November 27, 2026 [23].
• U.S. Drug Enforcement Administration (DEA) governs controlled-substance dispensing — registration, security, recordkeeping, and diversion prevention [24].
• Centers for Medicare & Medicaid Services (CMS) sets reimbursement and rules for Medicare Part D and Medicaid — the payers behind a large share of prescriptions — including the DIR reform and the IRA Part D redesign [19].
• Health Insurance Portability and Accountability Act (HIPAA) requires pharmacies to safeguard protected health information in covered electronic transactions [25].
• 340B drug-pricing program (discounts for certain safety-net providers) and state scope-of-practice rules also shape which entities dispense and at what cost.
• Opioid liability. Chains paid multibillion-dollar opioid settlements; opioid litigation was a direct contributor to Rite Aid's collapse [13].
• PBM and competition policy — the fastest-moving front. Because PBMs sit between payers and pharmacies, they are the focus of intense state and federal action, and the FTC and Department of Justice review pharmacy/PBM mergers and vertical integration. The three largest PBMs (CVS Caremark, Express Scripts, OptumRx) control roughly 80% of U.S. prescription claims [17]. The FTC has published interim staff reports (2024 and 2025) on PBM concentration, specialty-drug markups, and spread pricing [20][21], and reached a 2026 settlement with Caremark resolving part of its insulin-pricing case [22]. Legislative and state action includes Consolidated Appropriations Act, 2026 provisions classifying PBMs as ERISA fiduciaries and requiring 100% rebate pass-through to plan sponsors (phasing in 2028–2029), a 10-year FTC consent order against Express Scripts, Alabama's requirement that PBMs pay independents at least the Medicaid rate plus a $10.64 dispensing fee (effective October 2025), and Idaho's ban on spread pricing [18]. For dispensers, tighter PBM rules are broadly a potential tailwind, since they aim to raise and stabilize pharmacy pay.

8. Competitive dynamics and consolidation

Retail pharmacies compete on location, hours, convenience, pharmacist service, speed, prescription availability, price, insurance-network access, assortment, digital tools, and trust. Scale improves purchasing, technology, central fulfillment, payer negotiations, and data; local operators compete on relationships and community access. The past three years produced the most dramatic reshaping of U.S. retail pharmacy in a generation:

• The Big Three chains became a Big One-and-a-half. Rite Aid liquidated (2025) [13], Walgreens went private under Sycamore Partners (2025) [12], and CVS is now the dominant listed chain, holding over 26% of U.S. prescription-drug revenue [8]. CVS is itself closing hundreds of stores (271 planned closures tied to 2025 restructuring) [9].
• Vertical integration is the winning structure. The top four dispensers — CVS, Walgreens, Cigna, and UnitedHealth — account for about half of all U.S. dispensing revenue, and the top 15 for roughly three-quarters [7]. The integrated PBM-plus-pharmacy model out-earns the standalone store.
• Grocery and mass merchants keep taking share. Walmart is the clear #3 dispenser at ~10% of the market [29], and grocery/club pharmacies (Kroger, Costco, Publix, Albertsons) have grown faster than traditional chains — dispensing prescriptions as a loss-leading traffic driver they subsidize with grocery margin. Regional grocers are also merging for pharmacy scale and loyalty data (Kroger–Giant Eagle) [30].
• Online entrants nibble from a small base. Amazon Pharmacy, Cost Plus Drugs, and venture-funded startups have drawn more than $3 billion in capital but still represent only a few billion dollars of a ~$300 billion market [28] — disruptive on price and convenience, not yet on scale.
• Independents are squeezed but resilient. Independents fell to about 18,984 stores (mid-2024), losing more than one per day [14], yet collectively still outnumber any single chain and anchor rural and underserved markets [14].
• Access is deteriorating. Nearly one in three U.S. retail pharmacies has closed since 2010; about 50 million Americans (one in seven) now live in a "pharmacy desert," and independents are more than twice as likely to close [15]. In 2024–2025 closures shifted from suburban to urban low-income neighborhoods [15].

The likely result: a smaller number of scaled, vertically integrated platforms alongside a persistent local and specialty-pharmacy tail.

9. Risks

• Reimbursement compression. The central risk: PBMs and payers continue to pay less per prescription than it costs to dispense on many drugs, especially brand and specialty; clawbacks, audits, and formulary/network changes can cut profit even as volume rises [20][21].
• PBM leverage and vertical conflicts. Standalone dispensers negotiate against integrated rivals who both set their reimbursement and compete for their patients.
• Regulatory whipsaw. PBM reform could raise pharmacy pay — or misfire; the IRA reshapes Part D economics in ways still being absorbed; and drug-pricing politics (e.g., "most favored nation" and price-comparison initiatives) plus 340B changes add uncertainty [18][19].
• Fixed-cost store networks. Leases, rent, utilities, security, and shrink create operating leverage when sales shift to mail or online, and underperforming locations force closures.
• Labor and service pressure. Pharmacists earn a median ~$137,480 (May 2024) [26]; retail pharmacy shed roughly 8,500 jobs in 2024 (after ~4,800 in 2023) as chains cut hours amid staffing strain and worker walkouts [27]. Shortages and workload can damage both margins and retention.
• Drug supply and inventory risk. Shortages, recalls, counterfeits, cold-chain failures, and controlled-substance diversion can disrupt sales and create liability [23][24].
• GLP-1 margin dilution. Booming demand for high-cost weight-loss/diabetes drugs raises revenue but can compress blended margin.
• Data and cyber risk. Pharmacy systems hold sensitive health and payment data; breaches carry regulatory penalties, remediation costs, and reputational damage [25].
• Legacy liabilities and leverage. Opioid settlements remain a drag and were fatal to Rite Aid [13]; and highly leveraged private ownership can accelerate closures and asset sales when reimbursement weakens.
• Execution risk on the pivot. Survivors are betting on clinical services and cost-plus transparency; those transitions are unproven at scale.

10. How to invest and the outlook

Public-market routes. There is no clean listed pure-play besides CVS Health (CVS), and even CVS is really an insurer-PBM-pharmacy conglomerate where the retail counter is the smallest profit engine. The main mistake public investors make is valuing these consolidated companies as if all revenue came from retail pharmacies. Analyze the pharmacy segment on its own — prescription volume, reimbursement per script, gross margin after PBM adjustments, payer and generic/specialty mix, front-store performance, store productivity, lease obligations, capital spending, debt, and regulatory exposure. Investors chasing the drug-benefit profit pool that dominates this industry typically look to Cigna (CI) and UnitedHealth (UNH) for Express Scripts and OptumRx, though those are primarily health-insurance stocks; Walmart (WMT), Kroger (KR), Costco (COST), and Albertsons (ACI) carry pharmacy as a traffic-driving department without the standalone-chain fragility; Amazon (AMZN) offers optionality on online-pharmacy disruption from a tiny base; and GoodRx (GDRX) is an adjacent price-transparency play. Because pharmacy is a minority of every one of these except CVS, reserve share prices, dividend yields, and valuation multiples for security-specific analysis — the "industry" does not trade as a unit.

Private routes. Direct ownership usually means an independent community pharmacy (a small business; SBA small-business threshold $37.5 million in receipts [4]), typically affiliated with a distributor banner (Health Mart, Good Neighbor); institutional exposure runs through Sycamore Partners' Walgreens, regional chains and specialty platforms, pharmacy real estate, private credit, and venture stakes in online entrants such as Cost Plus Drugs. These are operationally hard businesses in a reimbursement squeeze — the private thesis rests largely on PBM reform lifting the pay floor, and diligence should center on: state pharmacy licenses and ownership rules; DEA registration and controlled-substance controls; payer/PBM contracts, reimbursement history, and post-sale adjustments; prescription-file retention and transfer risk; pharmacist recruitment and retention; inventory aging, working capital, and shortage exposure; lease terms and local competition; HIPAA, DSCSA, compounding, and billing compliance; and customer concentration by payer or plan. The $37.5 million size standard helps determine federal small-business status but is not a valuation benchmark.

Near-term drivers to watch:

• Whether PBM reform (federal rebate pass-through by 2028–2029, ERISA fiduciary status, and state dispensing-fee floors) actually raises and stabilizes reimbursement — the swing factor for every dispenser and the lifeline for independents.
• The industry-wide shift to cost-plus/transparent pricing and whether it protects margin as it spreads.
• The trajectory of GLP-1 demand and how much of that volume converts to profit versus dilutes it.
• Continued consolidation and store rationalization (CVS closures, grocery mergers, further chain shrinkage) versus political pressure over worsening pharmacy deserts [15].
• The pace at which mail, specialty, grocery, and online channels keep taking share from the traditional drugstore.

Base case. Prescription volume keeps growing with demographics and new drugs, but the value of dispensing continues to concentrate in vertically integrated PBM-pharmacy platforms and lower-cost mass/grocery/online channels. The strongest operators will combine reliable local access or specialty expertise with disciplined payer economics, efficient fulfillment, adequate staffing, and manageable fixed costs. Public exposure will stay mostly diversified and indirect; private ownership offers more operating control but less disclosure, less liquidity, and greater execution risk. The standalone corner drugstore — the archetype this NAICS code was built around — is the part of the industry under the most durable pressure, its fate hinging more on reimbursement policy than on foot traffic.

---

Sources

1. U.S. Census Bureau, 2022 NAICS Manual — 456110 Pharmacies and Drug Retailers (definition and cross-references, incl. exclusions to 524292, 456120/130/191/199, 424210). https://www.census.gov/naics/?details=456110&input=456110&year=2022
2. U.S. Census Bureau, County Business Patterns, 2023 (NAICS 456110 — establishments, employment, annual and first-quarter payroll). https://www.census.gov/data/datasets/2023/econ/cbp/2023-cbp.html
3. U.S. Census Bureau, 2022 Economic Census — Concentration of Largest Firms (NAICS 456110 — firms, receipts, CR4/CR8/CR20/CR50, HHI). https://data.census.gov/table/ECNSIZE2022.EC2200SIZECONCEN
4. U.S. Small Business Administration, Table of Size Standards (2023), NAICS 456110 ($37.5M average annual receipts). https://www.sba.gov/document/support-table-size-standards
5. U.S. Census Bureau, County Business Patterns: Coverage and Methodology (employer-establishment coverage; nonemployer exclusion). https://www.census.gov/programs-surveys/cbp/about.html
6. IQVIA Institute for Human Data Science, "The Use of Medicines in the U.S. 2024/2025" (7.1B scripts; $487B net spend, +11.4%; GLP-1 29% of growth; retail ~83% of use). https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-use-of-medicines-in-the-us-2024
7. Drug Channels Institute, "The Top 15 U.S. Pharmacies of 2024: Market Shares and Revenues," March 2025 (~$683B dispensing revenue; top-4/top-15 shares; integrated PBM-pharmacy groups). https://www.drugchannels.net/2025/03/the-top-15-us-pharmacies-of-2024-market.html
8. Statista, "Largest pharmacies in the U.S. by prescription drug market share, 2025" (CVS >26%). https://www.statista.com/statistics/734171/pharmacies-ranked-by-rx-market-share-in-us/
9. CVS Health Corporation, Form 10-K (FY2024) and Q4/full-year 2024 earnings release (~9,000 stores; segment revenue; store closures; vaccinations). https://www.cvshealth.com/content/dam/enterprise/cvs-enterprise/pdfs/2025/Q4-2024-Earnings-Release.pdf
10. CVS Health Corporation, "Reports Fourth Quarter and Full-Year 2025 Results," February 2026, and FY2025 Form 10-K (cost-based reimbursement transition; ~1.8B 30-day-equivalent scripts). https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm
11. Walgreens Boots Alliance, Inc., Form 10-K (fiscal year ended August 31, 2024) (8,560 U.S. locations). https://www.sec.gov/Archives/edgar/data/1618921/000161892124000084/wba-20240831.htm
12. Walgreens Boots Alliance / Sycamore Partners merger (announced March 2025; closed August 28, 2025; up to $23.7B). https://corporate.walgreens.com/news-and-stories/press-releases/2025/walgreen-co-to-operate-as-private-standalone-company-following-acquisition-by-sycamore-partners/
13. Fox Business, "Rite Aid files for bankruptcy for second time in less than 2 years" (2025), with subsequent full liquidation (final stores closed October 2025). https://www.foxbusiness.com/economy/rite-aid-files-bankruptcy-second-time-less-than-2-years
14. National Community Pharmacists Association, 2024 NCPA Digest (~18,984 independents June 2024; 19.7% gross margin 2023). https://ncpa.org/newsroom/news-releases/2024/10/27/ncpa-releases-2024-digest-report
15. USC Schaeffer Center / Health Affairs, "Nearly 1 in 3 Retail Pharmacies Have Closed Since 2010," December 2024 (pharmacy deserts; ~50M affected). https://schaeffer.usc.edu/research/pharmacy-closures-united-states-health-affairs/
16. The National Desk, "Alarming number of pharmacies closing nationwide" (2,200+ closures in 2024). https://thenationaldesk.com/news/spotlight-on-america/alarming-number-of-pharmacies-closing-nationwide-leaving-more-pharmacy-deserts
17. KFF, "What to Know About Pharmacy Benefit Managers (PBMs) and Federal Efforts at Regulation," and Modern Healthcare on PBM legislation (three PBMs ~80% of claims). https://www.kff.org/other-health/what-to-know-about-pharmacy-benefit-managers-pbms-and-federal-efforts-at-regulation/
18. Mintz, "PBM Policy and Legislative Update — Summer/Fall 2025" (CAA 2026 fiduciary/rebate provisions; FTC Express Scripts consent order; Alabama $10.64 dispensing fee; Idaho spread-pricing ban), November 2025. https://www.mintz.com/insights-center/viewpoints/2025-11-04-pbm-policy-and-legislative-update-summer-fall-2025
19. KFF, "Changes to Medicare Part D in 2024 and 2025 Under the Inflation Reduction Act," and CMS, "Final CY2025 Part D Redesign Program Instructions Fact Sheet" ($2,000 cap; $35 insulin; point-of-sale DIR). https://www.kff.org/medicare/changes-to-medicare-part-d-in-2024-and-2025-under-the-inflation-reduction-act-and-how-enrollees-will-benefit/
20. Federal Trade Commission, Interim Staff Report on Prescription Drug Middlemen, July 2024. https://www.ftc.gov/news-events/news/press-releases/2024/07/ftc-releases-interim-staff-report-prescription-drug-middlemen
21. Federal Trade Commission, Second Interim Staff Report on Prescription Drug Middlemen, January 2025. https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-releases-second-interim-staff-report-on-prescription-drug-middlemen
22. Federal Trade Commission, "FTC Secures Major Settlement with Caremark," July 2026 (resolving part of the antitrust/insulin-pricing case). https://www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman
23. U.S. Food and Drug Administration, "Pharmacists: Utilize DSCSA Requirements to Protect Your Patients" (small-dispenser exemptions through Nov 27, 2026). https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/pharmacists-utilize-dscsa-requirements-protect-your-patients
24. U.S. Drug Enforcement Administration, Diversion Control Division (controlled-substance registration and rules). https://www.deadiversion.usdoj.gov/
25. U.S. Department of Health and Human Services, "The HIPAA Privacy Rule." https://www.hhs.gov/hipaa/for-professionals/privacy/index.html
26. U.S. Bureau of Labor Statistics, Occupational Outlook Handbook: Pharmacists (median wage $137,480, May 2024). https://www.bls.gov/ooh/healthcare/pharmacists.htm
27. Drug Channels, "Pharmacist Salaries and Employment in 2024: Retail Employment Collapse Offset by Hospital Boom," June 2025. https://www.drugchannels.net/2025/06/pharmacist-salaries-and-employment-in.html
28. U.S. Chamber of Commerce, "How Mark Cuban and Amazon's Online Pharmacies Unlock Growth Opportunities" (online-pharmacy market size; Cost Plus pricing model). https://www.uschamber.com/co/good-company/launch-pad/online-pharmacies-unlocking-growth-for-startups-and-legacy-businesses
29. Supermarket News, "Walmart should continue to lead the pharmacy sector: report" (~10% share; grocery pharmacy growth; Kroger specialty ~$3.2B). https://www.supermarketnews.com/nonfood-pharmacy/walmart-should-continue-to-lead-the-pharmacy-sector-report
30. The Kroger Co., "Kroger Announces Agreement to Acquire Giant Eagle," 2026 (subject to clearance; expected close 2027). https://ir.kroger.com/news/news-details/2026/Kroger-Announces-Agreement-to-Acquire-Giant-Eagle/default.aspx
31. Amazon Pharmacy, "How Amazon Pharmacy Works" (online dispensing, home delivery, PillPack, RxPass). https://pharmacy.amazon.com/how-it-works
32. Private grocer disclosures: Publix Super Markets, "Pharmacy Succession Planning" (employee-owned; acquisition program); H-E-B, "About H-E-B" (partner-owned); Meijer newsroom (family-owned). https://www.publix.com/pharmacy/pharmacy-succession-planning
33. U.S. Securities and Exchange Commission, Costco Wholesale Corporation Form 10-K (FY2025) and Walmart Inc. Form 10-K (FY2025) (pharmacy as ancillary/third-party-reimbursed operations). https://www.sec.gov/Archives/edgar/data/909832/000090983225000101/cost-20250831.htm